Table_1_CD86 Molecule Might Be a Novel Immune-Related Prognostic Biomarker for Patients With Bladder Cancer by Bioinformatics and Experimental Assays.xlsx

As one of the most common malignancies in the urinary system, bladder cancer (BC) occupies a high mortality and recurrence rate. BC carries an ominous prognosis. Thus, we aimed to identify a novel immune-related prognostic biomarker and therapeutic target for immunotherapy in the present study. We first constructed a co-expression network based on immune-related genes (IRGs). Two key modules showed high association with the clinical feature interested us most were further identified. Forty-five IRGs were screened out and regarded as hub genes in the co-expression network. We further constructed a protein-protein interaction (PPI) network, and five independent methods were used for hub gene identification. Three hub genes were identified in the present study. CD86 molecule (CD86) was screened out by performing overall survival (OS) analysis. Subsequent analyses by using some bioinformatics and experimental assays confirmed that CD86 was an immune-related prognostic biomarker, which might be a novel target for immunotherapy in BC. A small molecule drug named suloctidil was also identified, which showed potential for BC treatment.

膀胱癌（BC）作为泌尿系统中最为常见的恶性肿瘤之一，其具有较高的死亡率与复发率，预后堪忧。鉴于此，本研究旨在识别一种新的与免疫相关的预后生物标志物及免疫治疗中的治疗靶点。首先，我们基于免疫相关基因（IRGs）构建了共表达网络，并进一步确定了与我们所关注的临床特征高度相关的两个关键模块。在共表达网络中筛选出45个IRGs，并将其视为枢纽基因。随后，我们构建了蛋白质-蛋白质相互作用（PPI）网络，并采用五种独立方法进行枢纽基因的识别。本研究中确定了三个枢纽基因。通过总生存期（OS）分析筛选出CD86分子（CD86）。后续通过生物信息学和实验检测的分析确认，CD86是一种与免疫相关的预后生物标志物，可能成为膀胱癌免疫治疗的新型靶点。此外，还发现了一种名为suloctidil的小分子药物，其在膀胱癌治疗中展现出潜在的应用价值。